SCHEMBL19962926

SCHEMBL19962926

CCCn1cc(-n2cc(-c3ccc(S(=O)(=O)C4CC4)cc3)cn2)ccc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MELK Q14680 3/20 0.45
▸ CREBBP Q92793 1/20 0.35
▸ DRD2 P14416 1/20 0.33
▸ ADORA2A P29274 4/20 0.33
▸ ADORA2B P29275 4/20 0.33
▸ ADORA1 P30542 4/20 0.33
▸ ADORA3 P0DMS8 2/20 0.33
▸ NPY5R Q15761 1/20 0.33
▸ UCHL1 P09936 1/20 0.33
▸ USP30 Q70CQ3 1/20 0.33
▸ MAPKAPK2 P49137 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ ALOX5 P09917 1/20 0.32
▸ CCR6 P51684 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ AXL P30530 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ TYRO3 Q06418 1/20 0.32
▸ MERTK Q12866 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19951564 0.85 MELK (0.49) MELKCREBBPADORA2AADORA2BADORA1
SCHEMBL19962966 0.85 MELK (0.35) MELKDRD2KCNH2FLT3
SCHEMBL19962909 0.83 MELK (0.46) MELKCREBBPADORA2AADORA2BADORA1
SCHEMBL19962898 0.83 DRD2 (0.37) MELKDRD2
SCHEMBL19962967 0.82 GABRA2 (0.38) MELKDRD2USP30KCNH2
SCHEMBL19962964 0.82 DRD2 (0.37) MELKCREBBPDRD2
SCHEMBL19963011 0.82 DRD2 (0.39) MELKCREBBPDRD2AXLTYRO3
SCHEMBL21130682 0.82 AXL (0.33) MELKDRD2KCNH2AXLFLT3
SCHEMBL19962907 0.82 PIK3CA (0.35) MELKDRD2AXLFLT3TYRO3
SCHEMBL19962958 0.81 DRD2 (0.38) MELKCREBBPDRD2AXLTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339142-B2 Di-substituted pyrazole compounds for the treatment of diseases FGH BIOTECH, INC. (US) 2022-05-24 — — US disclosed
WO-2020132700-A1 METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF Fgh Biotech Inc. (US) 2020-06-25 — — WO disclosed
US-20190194167-A1 DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES FGH BIOTECH, INC. 2019-06-27 — — US disclosed
WO-2018049080-A1 DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES FGH BIOTECH, INC. (US) 2018-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339142-B2 Di-substituted pyrazole compounds for the treatment of diseases SREBF1, SREBF2, CYP27A1 MELK 1854/4885CREBBP 136/4885DRD2 4559/4885
US-20190194167-A1 DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES SREBF1, SREBF2, CYP27A1 MELK 1854/4885CREBBP 136/4885DRD2 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback